Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 27

1.

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.

Thatcher N, Hirsch FR, Luft AV, Szczesna A, Ciuleanu TE, Dediu M, Ramlau R, Galiulin RK, Bálint B, Losonczy G, Kazarnowicz A, Park K, Schumann C, Reck M, Depenbrock H, Nanda S, Kruljac-Letunic A, Kurek R, Paz-Ares L, Socinski MA; SQUIRE Investigators..

Lancet Oncol. 2015 Jul;16(7):763-74. doi: 10.1016/S1470-2045(15)00021-2.

PMID:
26045340
2.

Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.

Paz-Ares L, Mezger J, Ciuleanu TE, Fischer JR, von Pawel J, Provencio M, Kazarnowicz A, Losonczy G, de Castro G Jr, Szczesna A, Crino L, Reck M, Ramlau R, Ulsperger E, Schumann C, Miziara JE, Lessa ÁE, Dediu M, Bálint B, Depenbrock H, Soldatenkova V, Kurek R, Hirsch FR, Thatcher N, Socinski MA; INSPIRE investigators..

Lancet Oncol. 2015 Mar;16(3):328-37. doi: 10.1016/S1470-2045(15)70046-X.

PMID:
25701171
3.

Randomized, double-blind, phase II trial comparing gemcitabine-cisplatin plus the LTB4 antagonist LY293111 versus gemcitabine-cisplatin plus placebo in first-line non-small-cell lung cancer.

Jänne PA, Paz-Ares L, Oh Y, Eschbach C, Hirsh V, Enas N, Brail L, von Pawel J.

J Thorac Oncol. 2014 Jan;9(1):126-31. doi: 10.1097/JTO.0000000000000037.

4.

Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.

Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, Nawrocki S, Ciuleanu TE, Bosquée L, Trigo JM, Spira A, Tremblay L, Nyman J, Ramlau R, Wickart-Johansson G, Ellis P, Gladkov O, Pereira JR, Eberhardt WE, Helwig C, Schröder A, Shepherd FA; START trial team..

Lancet Oncol. 2014 Jan;15(1):59-68. doi: 10.1016/S1470-2045(13)70510-2.

PMID:
24331154
5.

The validation of estrogen receptor 1 mRNA expression as a predictor of outcome in patients with metastatic non-small cell lung cancer.

Atmaca A, Al-Batran SE, Wirtz RM, Werner D, Zirlik S, Wiest G, Eschbach C, Claas S, Hartmann A, Ficker JH, Jäger E, Brueckl WM.

Int J Cancer. 2014 May 15;134(10):2314-21. doi: 10.1002/ijc.28571.

6.
7.

A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer.

Schuette WH, Gröschel A, Sebastian M, Andreas S, Müller T, Schneller F, Guetz S, Eschbach C, Bohnet S, Leschinger MI, Reck M.

Clin Lung Cancer. 2013 May;14(3):215-23. doi: 10.1016/j.cllc.2012.10.001.

PMID:
23332288
8.

Topotecan/cisplatin compared with cisplatin/etoposide as first-line treatment for patients with extensive disease small-cell lung cancer: final results of a randomized phase III trial.

Fink TH, Huber RM, Heigener DF, Eschbach C, Waller C, Steinhauer EU, Virchow JC, Eberhardt F, Schweisfurth H, Schroeder M, Ittel T, Hummler S, Banik N, Bogenrieder T, Acker T, Wolf M; “Aktion Bronchialkarzinom” (ABC Study Group)..

J Thorac Oncol. 2012 Sep;7(9):1432-9.

9.

Tasisulam sodium (LY573636 sodium) as third-line treatment in patients with unresectable, metastatic non-small-cell lung cancer: a phase-II study.

Scagliotti GV, Ilaria R Jr, Novello S, von Pawel J, Fischer JR, Ermisch S, de Alwis DP, Andrews J, Reck M, Crino L, Eschbach C, Manegold C.

J Thorac Oncol. 2012 Jun;7(6):1053-7. doi: 10.1097/JTO.0b013e3182519d79.

10.

FoxO1 induces Ikaros splicing to promote immunoglobulin gene recombination.

Alkhatib A, Werner M, Hug E, Herzog S, Eschbach C, Faraidun H, Köhler F, Wossning T, Jumaa H.

J Exp Med. 2012 Feb 13;209(2):395-406. doi: 10.1084/jem.20110216.

11.

A phase II randomized study of cisplatin-pemetrexed plus either enzastaurin or placebo in chemonaive patients with advanced non-small cell lung cancer.

Vansteenkiste J, Ramlau R, von Pawel J, San Antonio B, Eschbach C, Szczesna A, Kennedy L, Visseren-Grul C, Chouaki N, Reck M.

Oncology. 2012;82(1):25-9. doi: 10.1159/000335268.

PMID:
22269428
12.

Associative learning between odorants and mechanosensory punishment in larval Drosophila.

Eschbach C, Cano C, Haberkern H, Schraut K, Guan C, Triphan T, Gerber B.

J Exp Biol. 2011 Dec 1;214(Pt 23):3897-905. doi: 10.1242/jeb.060533.

13.

A combined perceptual, physico-chemical, and imaging approach to 'odour-distances' suggests a categorizing function of the Drosophila antennal lobe.

Niewalda T, Völler T, Eschbach C, Ehmer J, Chou WC, Timme M, Fiala A, Gerber B.

PLoS One. 2011;6(9):e24300. doi: 10.1371/journal.pone.0024300.

14.

Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study.

O'Byrne KJ, Gatzemeier U, Bondarenko I, Barrios C, Eschbach C, Martens UM, Hotko Y, Kortsik C, Paz-Ares L, Pereira JR, von Pawel J, Ramlau R, Roh JK, Yu CT, Stroh C, Celik I, Schueler A, Pirker R.

Lancet Oncol. 2011 Aug;12(8):795-805. doi: 10.1016/S1470-2045(11)70189-9.

PMID:
21782507
15.

Efficient generation of B lymphocytes by recognition of self-antigens.

Eschbach C, Bach MP, Fidler I, Pelanda R, Köhler F, Rajewsky K, Jumaa H.

Eur J Immunol. 2011 Aug;41(8):2397-403. doi: 10.1002/eji.201041344.

16.

The similarity between odors and their binary mixtures in Drosophila.

Eschbach C, Vogt K, Schmuker M, Gerber B.

Chem Senses. 2011 Sep;36(7):613-21. doi: 10.1093/chemse/bjr016.

17.

A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer.

Reck M, Kaiser R, Eschbach C, Stefanic M, Love J, Gatzemeier U, Stopfer P, von Pawel J.

Ann Oncol. 2011 Jun;22(6):1374-81. doi: 10.1093/annonc/mdq618.

18.

N-linked glycosylation selectively regulates autonomous precursor BCR function.

Ubelhart R, Bach MP, Eschbach C, Wossning T, Reth M, Jumaa H.

Nat Immunol. 2010 Aug;11(8):759-65. doi: 10.1038/ni.1903.

PMID:
20622883
19.

Pemetrexed in the treatment of malignant mesothelioma: results from an expanded access program in Germany.

Reck M, Stahel RA, von Pawel J, Karthaus M, Korfee S, Serke M, Schuette WH, Eschbach C, Fink TH, Leschinger MI, Manegold C.

Respir Med. 2010 Jan;104(1):142-8. doi: 10.1016/j.rmed.2009.07.019.

20.

Differential conditioning and long-term olfactory memory in individual Camponotus fellah ants.

Josens R, Eschbach C, Giurfa M.

J Exp Biol. 2009 Jun;212(Pt 12):1904-11. doi: 10.1242/jeb.030080.

Items per page

Supplemental Content

Loading ...
Support Center